Deerfield Beach, FL -- (SBWIRE) -- 07/16/2015 -- Market Research report On "Brexpiprazole (Schizophrenia) - Market Analysis and Forecast 2022" is a professional and Deep research report in this field

Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease. expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negativeand cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.

Brexpiprazole is a D2-preferring D3/D2 receptor partial agonist in development by Otsuka. As a partial agonist, like cariprazine (a D3 partial agonist), brexpiprazole helps to stabilize dopaminergic tone in periods of hyperor hypoactivity. Brexpiprazole has broad activity across multiple monoamine systems, including 5-HT1A partial agonism and antagonism at 5-HT2A a1 receptors, which may lessen the occurrence of EPS, although it acts on D2 receptors (Stahl, 2013). Brexpiprazole is also an antagonist at 5-HT7 receptors, which may make it useful as an antidepressant. Given its diverse activity profile, it is also being investigated in dementia, ADHD, PTSD, sleep disorders, and MDD. As its name suggests, brexpiprazole may be considered as a successor to Otsuka's Abilify (aripiprazole), which faces patent expiration in April 2015.

Visit Complete Report :

http://www.marketresearchstore.com/report/brexpiprazole-forecast-and-market-analysis-to-20907

Scope

Overview of Schizophrenia, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on Brexpiprazole including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for Brexpiprazole for the top seven countries from 2012 to 2022.

Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for Schizophrenia

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of Brexpiprazole performance

Obtain sales forecast for Brexpiprazole from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Get Sample Copy of Report : http://www.marketresearchstore.com/report/brexpiprazole-forecast-and-market-analysis-to-20907#requestSample